Praluent (Alirocumab) Adult Dosing: Complete Guide for Ages 30 to 49

Alirocumab is the generic name for the brand-name drug Praluent, a fully human monoclonal antibody (an injectable biologic, not a small-molecule pill) that inhibits PCSK9, a protein that otherwise degrades LDL receptors on liver cells. It is FDA-approved as an add-on to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering. It is not the same molecule as evolocumab (Repatha), a related but separately dosed PCSK9 inhibitor.

Direct answer: The FDA-approved starting dose of alirocumab is 75 mg by subcutaneous injection every two weeks. If LDL-C has not reached the individualized goal after 4 to 8 weeks, the label allows titration to 150 mg every two weeks, and a once-monthly 300 mg regimen (given as two 150 mg injections at one visit) is pharmacokinetically equivalent to 150 mg every two weeks. This dosing framework comes from prescribing guidance and from the ODYSSEY OUTCOMES trial, which used the same 75-mg-start, 8-week-check, uptitrate-if-needed algorithm in 18,924 post-acute-coronary-syndrome patients and found a 15% relative reduction in major cardiovascular events over a median 2.8 years. [6]

There is no dosing regimen specific to ages 30 to 49. The FDA label and the pivotal trials dose by clinical indication and LDL-C response, not by age band. Adults in this age range are a relevant audience because this is when HeFH is often first diagnosed and when a first ASCVD event commonly triggers secondary-prevention therapy, but nothing in the label or trial data changes the dose because a patient falls in this age window.

What the FDA label says about starting and titrating the dose

The FDA-approved prescribing information specifies 75 mg subcutaneously every two weeks as the standard starting dose for HeFH or ASCVD patients needing additional LDL-C lowering on top of maximally tolerated statin therapy. After a minimum of 4 weeks, if the LDL-C response is insufficient against the individualized goal, the clinician may increase to 150 mg every two weeks. The label also permits starting directly at 150 mg every two weeks when a larger LDL-C reduction is anticipated to be needed, such as in patients with markedly elevated baseline LDL-C, per prescribing guidance.

Homozygous FH follows a separate dosing framework not covered here and requires specialist management.

The 150 mg every-two-weeks dose

When 75 mg does not reach the individualized LDL-C target after 4 to 8 weeks, the label-directed step is uptitration to 150 mg every two weeks. In the pivotal efficacy trial pooled analysis, alirocumab produced substantial mean LDL-C reductions from baseline at the 150 mg dose, though the exact percentage varies by trial population and background statin intensity; readers should treat any single percentage as an average from a specific trial cohort rather than a guarantee for an individual patient. [4]

The 2018 ACC/AHA cholesterol guideline recommends considering a PCSK9 inhibitor when maximally tolerated statin plus ezetimibe does not achieve at least a 50% LDL-C reduction, or when LDL-C remains at or above 70 mg/dL in very high-risk ASCVD patients. [2][3] This is a guideline recommendation from an accountable professional society, not an FDA label requirement, and payers may apply their own prior-authorization criteria on top of it.

Some clinicians start ASCVD patients with substantially elevated baseline LDL-C directly at 150 mg every two weeks rather than 75 mg, which the label permits, in order to reach goal faster. Whether that approach is right for a given patient is a decision for the prescribing clinician, not something a general guide can determine.

The 300 mg once-monthly option

A single 300 mg dose given subcutaneously once monthly, administered as two separate 150 mg injections at two different sites during the same session, is described in prescribing guidance as an alternative to 150 mg every two weeks with equivalent LDL-C lowering. The two injections should be completed at the same visit; the label does not support spacing them apart by hours or days.

A monthly schedule may suit patients who find a biweekly injection routine harder to sustain. One published survey of PCSK9 inhibitor users has been cited in some secondary sources as linking dosing frequency to adherence lapses; because the discovery process for this article could not independently confirm the exact figures reported for that survey, any specific percentage from it should be treated as unverified until an editor checks the primary source.

ODYSSEY OUTCOMES: the trial behind the cardiovascular claim

ODYSSEY OUTCOMES enrolled 18,924 patients who had an acute coronary syndrome 1 to 12 months before randomization and were on high-intensity or maximum-tolerated statin therapy. Patients were randomized to alirocumab, starting at 75 mg every two weeks with blinded uptitration to 150 mg if LDL-C stayed at or above 50 mg/dL at 8 weeks, or to placebo. The primary endpoint was a composite of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or hospitalization for unstable angina. [6]

At a median follow-up of 2.8 years, alirocumab reduced the primary composite endpoint by 15% relative to placebo (hazard ratio 0.85, 95% CI 0.78-0.93). All-cause mortality was also reduced (hazard ratio 0.85, 95% CI 0.73-0.98), with a trend toward greater absolute benefit in patients with higher baseline LDL-C. [6] The trial authors concluded, in substance, that alirocumab reduced recurrent ischemic events and death in recent-ACS patients with elevated LDL-C despite intensive statin therapy; readers who want the exact published wording should consult the original NEJM article rather than a secondhand quotation. [6]

The trial's dosing algorithm mirrors the current label: start at 75 mg every two weeks, recheck at 8 weeks, uptitrate if needed. That parallel is what lets this trial's outcome data speak to the label's dosing sequence, though ODYSSEY OUTCOMES was not designed or powered to report results separately for a 30-49 age subgroup, and no such subgroup breakdown is cited here.

How alirocumab is injected

The following reflects standard administration instructions.

• Site selection. Abdomen (at least two inches from the navel), outer thigh, or outer upper arm, rotating sites with each injection.
• Temperature. Let the pre-filled pen sit at room temperature for 30 to 40 minutes before injecting; injecting a cold solution is more uncomfortable.
• Skin prep. Clean with an alcohol swab and let it dry before injecting.
• Technique. Place the auto-injector flat against the skin at a 90-degree angle, press until it clicks, and hold in place for the duration specified in the device instructions to ensure full delivery.
• After injection. Do not rub the site. Mild redness or a trace of bleeding is expected.
• Timing with oral therapy. No timing separation from statins or ezetimibe is required.

For the 300 mg monthly regimen, both injections should be completed in the same session at two different sites.

Pharmacokinetics and drug interactions

Alirocumab is a fully human IgG1 monoclonal antibody against PCSK9. By binding circulating PCSK9, it prevents PCSK9 from promoting degradation of hepatic LDL receptors, increasing LDL receptor recycling and lowering plasma LDL-C, as described in pharmacology reviews of PCSK9 inhibition.

After a 75 mg subcutaneous dose, peak serum concentration occurs at roughly 3 to 7 days, and the elimination half-life is approximately 17 to 20 days, which is the pharmacologic rationale for every-two-week dosing. Steady state is typically reached after two to three doses. Prescribing guidance states no dose adjustment is needed for mild-to-moderate renal impairment or mild hepatic impairment.

Because alirocumab is not metabolized by cytochrome P450 enzymes, it has no known clinically significant interaction with statins, ezetimibe, fibrates, or most other cardiovascular medications. Population pharmacokinetic modeling from the ODYSSEY program did not find a clinically meaningful effect of body weight on drug exposure or LDL-C response within the ranges studied, so routine weight-based dose adjustment is not part of the label.

Side effects and safety considerations

Across the ODYSSEY trial program, the most common adverse effect was injection-site reaction, reported in a higher proportion of alirocumab-treated patients than placebo-treated patients; nasopharyngitis, influenza, and urinary tract infection were also reported somewhat more often without a clear mechanistic explanation. [4] Serious hypersensitivity reactions, including angioedema, have been reported rarely; patients should be told to seek urgent care for signs of a systemic allergic reaction (facial or throat swelling, difficulty breathing, widespread hives) after any injection.

ODYSSEY OUTCOMES followed patients down to very low LDL-C levels without a group-level signal for cognitive decline, new-onset diabetes, or hemorrhagic stroke, and a prespecified neurocognitive substudy found no significant difference between groups. [6] This is trial-level, group-average evidence over a median 2.8 years; it does not establish long-term safety over the multi-decade horizon that a 30-year-old might spend on this drug, and that gap should be stated plainly rather than implied away.

Pregnancy and lactation. Alirocumab is not recommended during pregnancy or breastfeeding because human safety data are lacking. The 2018 ACC/AHA guideline advises stopping PCSK9 inhibitor therapy before attempting conception. [3] Given the 17-to-20-day half-life, several weeks off the drug are needed before it clears systemic circulation; the exact interval to recommend before conception attempts should be individualized with the prescribing clinician rather than taken as a fixed rule from this article.

What is established, what is plausible, and what is not established

• Established: the FDA-approved dosing sequence (75 mg every two weeks, optional uptitration to 150 mg every two weeks or an equivalent 300 mg monthly regimen); the ODYSSEY OUTCOMES finding of reduced major cardiovascular events in post-ACS patients on background statin therapy over a median 2.8 years; the absence of known CYP-mediated drug interactions. [6]
• Plausible but not proven by the cited evidence: that a monthly injection schedule meaningfully improves real-world adherence compared with biweekly dosing; that outcomes in a narrowly defined 30-49 age cohort mirror the trial-wide result exactly, since no age-stratified subgroup analysis is cited here.
• Not established: long-term (multi-decade) safety at very low LDL-C levels; a validated dosing modification specific to ages 30-49; the precise magnitude of any adherence effect attributed to dosing frequency, which requires verification against the original source before being cited as a number.

Clinician-discussion and monitoring framework

This framework outlines how to discuss alirocumab with your doctor and should not replace clinical judgment tailored to your specific situation. Your doctor will determine the appropriate alirocumab dose, LDL-C targets, and treatment schedule by considering your current statin therapy, existing health conditions, cardiovascular risk profile, and cholesterol goals.

Before the first injection, confirm with your prescriber:

• Which indication is documented (HeFH vs. established ASCVD), since this affects the LDL-C goal used to judge success.
• What statin (or documented statin-intolerance alternative) is in place, and at what intensity.
• Baseline fasting lipid panel and hepatic function results.
• Pregnancy status and contraception plans, if relevant.
• Who will observe or teach the first injection technique.

At the 4-to-8-week checkpoint (the label's titration decision point):

• A fasting LDL-C is drawn and compared against the individualized goal set by the prescriber (commonly under 70 mg/dL for very high-risk ASCVD per ACC/AHA guidance, or a separate target for HeFH in primary prevention). [2][3]
• If goal is met: continue current dose, no automatic increase.
• If goal is not met: the label supports uptitration to 150 mg every two weeks; this is a discussion point, not an automatic switch, since some patients and prescribers may instead reassess statin adherence or intensity first.

After any dose change:

• Repeat fasting LDL-C roughly 4 to 8 weeks later to confirm the new dose's effect, following the same logic as the initial titration check.

Ongoing (roughly every 6 to 12 months, per clinician judgment):

• Fasting lipid panel.
• Injection technique and adherence review.
• Screen for new risk factors that commonly emerge in adulthood (new hypertension, new diabetes diagnosis, weight change, smoking status change), any of which may prompt the clinician to revisit the overall treatment plan, not just the alirocumab dose.

Stop-and-call conditions (seek prompt medical attention, do not wait for a routine visit):

• Signs of a systemic allergic reaction after an injection (swelling of face or throat, difficulty breathing, widespread hives).
• Planning a pregnancy or a positive pregnancy test while on therapy.
• Two consecutive LDL-C results below 25 mg/dL, which prescribing guidance flags as a point to discuss dose reduction or discontinuation with the prescriber.
• New or worsening symptoms at the injection site that suggest infection rather than a typical local reaction (spreading redness, warmth, fever).

Where the label ends and individualized care begins: The FDA label defines the dose ladder (75 mg to 150 mg to 300 mg monthly) and the general population it applies to. It does not set a single universal LDL-C target, does not dictate exactly when to reassess statin therapy versus alirocumab dose, and does not address every comorbidity combination a given adult may have. Those judgments belong to the prescribing clinician working with the individual patient's full history.

Prior authorization and access

PCSK9 inhibitor access has historically involved insurer prior-authorization requirements, typically documenting a qualifying diagnosis, a minimum period on maximally tolerated statin therapy, and a qualifying LDL-C level, often with ezetimibe co-prescription required first. Approval-rate figures and the effect of professional-society prior-authorization guidance on those rates change over time and by payer; a reader relying on a specific approval-rate percentage should verify it against a current source rather than a historical figure, since payer policy is a volatile, date-sensitive fact that can shift after this article's publication date. Manufacturer copay assistance programs may be available for eligible commercially insured patients; eligibility and terms should be confirmed directly with the program.

Special situations worth raising with a prescriber

Statin intolerance. In the ODYSSEY ALTERNATIVE trial of statin-intolerant patients (N=314), alirocumab 75 mg every two weeks produced meaningfully greater LDL-C reduction than ezetimibe at 24 weeks. [10] This supports alirocumab as an option for genuinely statin-intolerant patients, usually alongside ezetimibe, as a clinical decision rather than a self-directed choice.

Type 2 diabetes. ODYSSEY OUTCOMES included a substantial proportion of patients with baseline diabetes, and the cardiovascular benefit was consistent across that subgroup; alirocumab dosing itself does not change based on diabetes status, and the drug does not affect glycemic control. [6]

Higher baseline LDL-C. Patients with markedly elevated LDL-C, such as those with HeFH not controlled on maximum statin plus ezetimibe, may be started at 150 mg every two weeks per prescribing guidance rather than titrating up from 75 mg. The expected percentage reduction from a given baseline varies by patient and should not be treated as a fixed formula; general trial-level reduction ranges are informative context, not an individualized prediction. [4]

This article is a general educational reference and does not replace individualized medical advice. Dosing, titration, and monitoring decisions should be made with a prescribing clinician based on the individual patient's diagnosis, lab results, and health history. This draft is pending qualified medical review.